Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.

Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.

PMID:
24463007
[PubMed - indexed for MEDLINE]
2.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

PMID:
21492444
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

PMID:
19609946
[PubMed - indexed for MEDLINE]
4.

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.

Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD.

Int J Cancer. 2007 May 1;120(9):1874-82.

PMID:
17266042
[PubMed - indexed for MEDLINE]
5.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

PMID:
21447808
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Estradiol rapidly activates Akt via the ErbB2 signaling pathway.

Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A.

Mol Endocrinol. 2003 May;17(5):818-30. Epub 2003 Jan 23. Retraction in: Mol Endocrinol. 2004 Aug;18(8):2096.

PMID:
12554767
[PubMed - indexed for MEDLINE]
7.

Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.

van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC.

Int J Cancer. 2012 Nov 1;131(9):1998-2007. doi: 10.1002/ijc.27489. Epub 2012 Mar 20.

PMID:
22328489
[PubMed - indexed for MEDLINE]
8.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

PMID:
17686159
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA.

Endocr Relat Cancer. 2008 Dec;15(4):985-1002. doi: 10.1677/ERC-07-0240. Epub 2008 Sep 29.

PMID:
18824559
[PubMed - indexed for MEDLINE]
Free Article
10.

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.

Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jücker M.

Cell Signal. 2011 Dec;23(12):1952-60. doi: 10.1016/j.cellsig.2011.07.003. Epub 2011 Jul 12.

PMID:
21777670
[PubMed - indexed for MEDLINE]
11.

Flotillin depletion affects ErbB protein levels in different human breast cancer cells.

Asp N, Pust S, Sandvig K.

Biochim Biophys Acta. 2014 Sep;1843(9):1987-96. doi: 10.1016/j.bbamcr.2014.04.013. Epub 2014 Apr 18.

PMID:
24747692
[PubMed - indexed for MEDLINE]
12.

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW.

Breast Cancer Res Treat. 2013 May;139(1):71-80. doi: 10.1007/s10549-013-2485-2. Epub 2013 Apr 23.

PMID:
23609470
[PubMed - indexed for MEDLINE]
13.

Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.

Glaros S, Atanaskova N, Zhao C, Skafar DF, Reddy KB.

Mol Endocrinol. 2006 May;20(5):996-1008. Epub 2006 Feb 2. Retraction in: Mol Endocrinol. 2008 Mar;22(3):772.

PMID:
16455819
[PubMed - indexed for MEDLINE]
14.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
[PubMed - indexed for MEDLINE]
Free Article
15.

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.

PMID:
20179226
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.

Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, Hampe C, Issad T.

PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013.

PMID:
23935944
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.

Ford CE, Ekström EJ, Andersson T.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24. doi: 10.1073/pnas.0809516106. Epub 2009 Feb 23. Retraction in: Ford CE, Ekström EJ, Anderson T. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22360.

PMID:
19237581
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.

Lu Y, Zhou H, Chen W, Zhang Y, Hamburger AW.

Breast Cancer Res Treat. 2011 Feb;126(1):27-36. doi: 10.1007/s10549-010-0873-4. Epub 2010 Apr 9.

PMID:
20379846
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

PMID:
24168763
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk